2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of test
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz WL, de Oliveira RD, da Silva PV, de Castro DB, de Souza Sampaio V, de Albuquerque BC, Ramos TCA, Fraxe SHH, da Costa CF, Naveca FG, Siqueira AM, de Araújo WN, Andrews JR, Cummings DAT, Ko AI, Croda J. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health - Americas 2021, 1: 100025. PMID: 34386791, PMCID: PMC8310555, DOI: 10.1016/j.lana.2021.100025.Peer-Reviewed Original ResearchSymptomatic SARS-CoV-2 infectionSARS-CoV-2 infectionTwo-dose scheduleTest-negative case-control studyEffectiveness of CoronaVacCase-control studyHealthcare workersVariant transmissionVaccine doseFirst doseSecond doseSample collection dateSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsDose of CoronaVacTest-negative studiesVaccine effectiveness estimatesEffectiveness of vaccinesRT-PCR testingCase-control pairsRT-PCR testMunicipal Health SecretarySARS-CoV-2 samplesNon-pharmaceutical interventionsPeriod 14 daysUnvaccinated individuals